NIR Research and Product Company Kiev, Ukraine (стр. 2 )

Mean values of biochemical plasma indices measured in patients with brain cancers after their receiving Bipexumâ therapy displayed no statistically confident alterations as compared with those before therapy (table 2).

The control group’s biochemical plasma indices did not statistically changed either, however, some decrease in hematocrit was noted. Based on the level of the activity of AST and ALT enzymes, clinical assays find out the soundness of liver function. Significant increase in the said enzymes' activity in the blood can, as a rule, signal severe liver damages, death of the large number of hepatocytes or badly impaired permeability of cell membranes.

Our investigations disclosed no Bipexumâ-caused statistically confident alterations in the AST and ALT plasma activity (table 3).

Table 3

Dynamics of AST and ALT Plasma Activity in Brain Cancer Patients as a Result of Bipexumâ Therapy

No.	Indices	Before Therapy, М±m	After Therapy, М±m	Р	Control Group, М±m	Р
1	AST, %	0.365 ± 0.057	0.314 ± 0.048	>0.05	0.487 ± 2.96	<0.05
2	ALT, %	0.364 ± 0.049	0.336 ± 0.052	>0.05	4.02 ± 0.15	<0.05
3	de Ritis AST / ALT ratio	1.00	0.934	>0.05	0.628	<0.05

However, individually analysing alterations in parameters after administering Bipexumâ it was found that the activity of plasma transaminases reduced in 80 % of those concerned to show that liver function improved.

Plasma AST and ALT activity in the brain cancer control group has been studied to disclose statistically confident increase in the activity of the said enzymes along with de Ritis ratio going down.

Studying findings of plasma protein exchange after Bipexumâ therapy for brain cancers it was found that the content of sulphhydryl groups (total, protein and non-protein) decreased in a statistically confident way (table 4) to signal slackened processes engaged in protein synthesis and the drug having anticancer activity.

Bipexumâ-caused alterations in plasma protein fractions have been individually analysed to display, in 80 % of those concerned, increase in both albumin content proving healthier liver function, and γ-globulin fraction of immunoglobulins that can be regarded as a factor contributing to strengthened klendusity.

The control group displayed alterations in protein fraction content of plasma appearing in the confident increase in β-globulin content and confident decrease in that of γ-globulins. Total protein and albumin content is slightly modified downward.

Immunologic indices were studied before and after Bipexumâ administration. The following factors were scanned: T-lymphocytes, T-helpers, T-suppressors, B-lymphocytes. The similar factors were looked into in patients given radiation and chemotherapy without Bipexumâ. This group showed pronounced negative dynamics as far as the cell link was concerned (suppressed T-lymphocytes – 33 % – 0.44), negative IRI dynamics (deep immunosuppression), pan-lymphopenia. The Bipexumâ takers' group displayed, as a rule, no negative dynamics of immunologic indices.

Table 4

The Way Plasma Protein Exchange Factors Change as a Result of Bipexumâ Therapy for Brain Cancers

No.	Factor	Before Therapy, М±m	After Therapy, М±m	Р	Control Group, М±m	Р
1	Total protein, g/l	59.97 ± 0.91	60.58 ±1.11	>0.05	57.84 ±1.04	>0.05
2	Albumins	58.09 ±1.71	59.38±1.57	>0.05	56.23 ± 1.21	>0.05
3	α Globulin	13.94 ±0.8	12.59 ±1.0	>0.05	14.95 ± 0.76	>0.05
4	β Globulin	11.80 ±0.86	10.88 ±0.87	>0.05	15.88±1.05	<0.05
5	γ Globulin	17.07 ± 1.51	17.23± 1.27	>0.05	12.42 ± 0.96	>0.05
6	A/G Ratio	1.44 ±0.1	1.50 ± 0.09	>0.05	1.29 ±0.08	>0.05
7	Total SH-groups, μmol/l	405 ± 39.31	327.11 ±30.59	<0.05	356.28 ± 29.41	<0.05
8	Protein SH-groups, μmol/l	340 ± 39.60	274.37 ± 29.50	<0.05	287.43 ± 29.88	<0.05
9	Non-protein SH-groups, μmol/l	81.59 ± 6.43	63.95 ±5.19	<0.05	68.75 ± 5.92	<0.05

So it can be said that chemotherapy and radiation therapy suppress bodily immunoprotection.

Administering Bipexumâ enables genetic and T-cell immunity to be improved (strengthened T-helpers, raised T - and B-lymphocyte level, intensified lymphocytic activity) (table 5).

Table 5

The Way Plasma Immunologic Values Change as a Result of Bipexumâ Therapy for Brain Cancers

No.	Factors	Before Therapy	After Therapy
1	T-, B-lymphocytes	62 %, 0.84	64 %, 0.98
2	T-helpers	24 %, 0.33	29 %, 0.47
3	T-suppressors	32 %, 0.42	29%, 0.41
4	Т-helpers/Т-suppressors ratio	0.78	1.15
5	Lymphocytic activity	24%, 0.16	34 %, 0.38

In general, clinical assays show that Bipexumâ therapy for brain cancers had marked impact neither on haemopoietic processes nor nitrogen-isolating function of kidneys, but rather demonstrated moderate hepatoprotective and anticancer effect and strengthened immunity.